Big drugmaker. High dividend yield. Promising new products.
All three apply to AbbVie Inc. (NYSE: ABBV). They also all apply to GlaxoSmithKline plc (NYSE: GSK). But while AbbVie stock has achieved solid gains so far in 2017, GlaxoSmithKline’s share price isn’t very far above where it started out the year. Past performance doesn’t necessarily make one stock better than the other, though. Which of these big pharma stocks is the smarter pick for investors now? Here’s how AbbVie and GlaxoSmithKline compare.